[Pharmacotherapy in personality disorders: methodological issues and results]

Area of Science:

• Psychiatry and Pharmacology
• Clinical Psychology and Psychopathology

Background:

• Pharmacotherapy for personality disorders is an emerging field, complementing psychological treatments.
• Addresses clinical needs for managing complex and challenging patient populations.
• Requires robust conceptual and methodological approaches for drug effect assessment.

Purpose of the Study:

• To review and classify current findings in the pharmacotherapy of personality disorders.
• To explore the efficacy of various drug classes across different personality disorder clusters (DSM-IV Axis-II).
• To identify symptom-oriented pharmacologic strategies and future research directions.

Main Methods:

• Review and synthesis of existing studies on pharmacotherapy for personality disorders.
• Classification of results based on DSM-IV Axis-II personality disorder categories.
• Evaluation of drug effects on specific symptoms like aggression, impulsivity, anxiety, and self-harm.

Main Results:

• Antidepressants show potential for anxiety and obsessive-compulsive traits in Cluster C disorders.
• Low-dose antipsychotics may benefit Cluster A disorders.
• Various agents (lithium, SSRIs, etc.) demonstrate partial efficacy for aggression and impulsivity in Cluster B disorders, particularly antisocial and borderline types. Antidepressants and antipsychotics show promise for self-harm and suicidal behaviors.

Conclusions:

• Pharmacotherapy for personality disorders is underexplored but holds future therapeutic potential.
• Medications can offer complementary treatment options for severe, chronic personality disorders.
• Further research is needed to develop effective psychopharmacological interventions.